Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis
AimsWe performed this meta-analysis to evaluate the efficacy and safety of glucagon-like peptide-1 receptor-agonists (GLP-1RA) treatment on cardio-metabolic parameters among antipsychotic-treated patients with schizophrenia.MethodsWe searched the Web of Science, Cochrane Central Register of Controll...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1153648/full |
| _version_ | 1797833052226846720 |
|---|---|
| author | Abdulrhman Khaity Nada Mostafa Al-dardery Khaled Albakri Omar A. Abdelwahab Mahmoud Tarek Hefnawy Yaman A. S. Yousef Ruaa E. Taha Sarya Swed Wael Hafez Wael Hafez Rene Hurlemann Rene Hurlemann Rene Hurlemann Mohamed E. G. Elsayed Mohamed E. G. Elsayed |
| author_facet | Abdulrhman Khaity Nada Mostafa Al-dardery Khaled Albakri Omar A. Abdelwahab Mahmoud Tarek Hefnawy Yaman A. S. Yousef Ruaa E. Taha Sarya Swed Wael Hafez Wael Hafez Rene Hurlemann Rene Hurlemann Rene Hurlemann Mohamed E. G. Elsayed Mohamed E. G. Elsayed |
| author_sort | Abdulrhman Khaity |
| collection | DOAJ |
| description | AimsWe performed this meta-analysis to evaluate the efficacy and safety of glucagon-like peptide-1 receptor-agonists (GLP-1RA) treatment on cardio-metabolic parameters among antipsychotic-treated patients with schizophrenia.MethodsWe searched the Web of Science, Cochrane Central Register of Controlled Trials, PubMed, PsycINFO, and Scopus for relevant Randomized Clinical trials (RCTs) from inception until 1 August 2022. Documents were screened for qualified articles, and all concerned outcomes were pooled as risk ratios (RR) or mean difference (MD) in the meta-analysis models using Review Manager (RevMan version 5.4).ResultsPooling data from 7 RCTs (398 patients) showed that GLP-1 RA was superior to placebo with regard to body weight [MD = - 4.68, 95% CI (-4.90,−4.46), P < 0.00001], waist circumference [MD = - 3.66, 95% CI (-3.89,−3.44), P < 0.00001], body mass index (BMI) [MD = - 1.09, 95% CI (-1.25,−0.93), P < 0.00001], systolic blood pressure (SBP) [MD = - 3.07, 95% CI (-3.61,−2.53), P < 0.00001], and diastolic blood pressure (DBP) [MD = - 2.02, 95% CI (-2.42,−1.62), P < 0.00001]. The total effect did not favor either of the two groups with respect to insulin and respiratory adverse events {[MD = - 0.06, 95% CI (-0.36, 0.24), p = 0.70], [RR = 0.66, 95% CI (0.31, 1.40), p = 0.28]; respectively}.ConclusionOur analysis revealed that GLP-1 RA treatment is safe and effective on cardio-metabolic parameters over control in antipsychotic-treated patients with schizophrenia. Nevertheless, the present evidence is not sufficient to confirm the safety and efficacy of GLP-1RA treatment on insulin and respiratory adverse events. Therefore, further studies are recommended.Systematic review registrationhttp://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42022333040. |
| first_indexed | 2024-04-09T14:18:37Z |
| format | Article |
| id | doaj.art-8bc063961cec4d8bb35fa017a3ffe66e |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-04-09T14:18:37Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-8bc063961cec4d8bb35fa017a3ffe66e2023-05-05T05:50:07ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402023-05-011410.3389/fpsyt.2023.11536481153648Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysisAbdulrhman Khaity0Nada Mostafa Al-dardery1Khaled Albakri2Omar A. Abdelwahab3Mahmoud Tarek Hefnawy4Yaman A. S. Yousef5Ruaa E. Taha6Sarya Swed7Wael Hafez8Wael Hafez9Rene Hurlemann10Rene Hurlemann11Rene Hurlemann12Mohamed E. G. Elsayed13Mohamed E. G. Elsayed14Faculty of Medicine, Elrazi University, Khartoum, SudanFaculty of Medicine, Fayoum University, Fayoum, EgyptFaculty of Medicine, The Hashemite University, Zarqa, JordanFaculty of Medicine, Al-Azhar University, Cairo, EgyptFaculty of Medicine, Zagazig University, Zagazig, EgyptFaculty of Medicine, Elrazi University, Khartoum, SudanFaculty of Medicine, Khartoum University, Khartoum, SudanFaculty of Medicine, Aleppo University, Aleppo, SyriaNMC Royal Hospital, Khalifa City, Abu Dhabi, United Arab EmiratesMedical Research Division, Department of Internal Medicine, The National Research Centre, Cairo, Egypt0Department of Psychiatry, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany1Department of Psychiatry, University Hospital Bonn, Bonn, Germany2Research Center Neurosensory Science, Carl von Ossietzky University Oldenburg, Oldenburg, Germany0Department of Psychiatry, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany3Department of Psychiatry and Psychotherapy III, University of Ulm, Ulm, GermanyAimsWe performed this meta-analysis to evaluate the efficacy and safety of glucagon-like peptide-1 receptor-agonists (GLP-1RA) treatment on cardio-metabolic parameters among antipsychotic-treated patients with schizophrenia.MethodsWe searched the Web of Science, Cochrane Central Register of Controlled Trials, PubMed, PsycINFO, and Scopus for relevant Randomized Clinical trials (RCTs) from inception until 1 August 2022. Documents were screened for qualified articles, and all concerned outcomes were pooled as risk ratios (RR) or mean difference (MD) in the meta-analysis models using Review Manager (RevMan version 5.4).ResultsPooling data from 7 RCTs (398 patients) showed that GLP-1 RA was superior to placebo with regard to body weight [MD = - 4.68, 95% CI (-4.90,−4.46), P < 0.00001], waist circumference [MD = - 3.66, 95% CI (-3.89,−3.44), P < 0.00001], body mass index (BMI) [MD = - 1.09, 95% CI (-1.25,−0.93), P < 0.00001], systolic blood pressure (SBP) [MD = - 3.07, 95% CI (-3.61,−2.53), P < 0.00001], and diastolic blood pressure (DBP) [MD = - 2.02, 95% CI (-2.42,−1.62), P < 0.00001]. The total effect did not favor either of the two groups with respect to insulin and respiratory adverse events {[MD = - 0.06, 95% CI (-0.36, 0.24), p = 0.70], [RR = 0.66, 95% CI (0.31, 1.40), p = 0.28]; respectively}.ConclusionOur analysis revealed that GLP-1 RA treatment is safe and effective on cardio-metabolic parameters over control in antipsychotic-treated patients with schizophrenia. Nevertheless, the present evidence is not sufficient to confirm the safety and efficacy of GLP-1RA treatment on insulin and respiratory adverse events. Therefore, further studies are recommended.Systematic review registrationhttp://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42022333040.https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1153648/fullschizophreniasystematic reviewmeta-analysisGLP-1 receptor agoniststreatment |
| spellingShingle | Abdulrhman Khaity Nada Mostafa Al-dardery Khaled Albakri Omar A. Abdelwahab Mahmoud Tarek Hefnawy Yaman A. S. Yousef Ruaa E. Taha Sarya Swed Wael Hafez Wael Hafez Rene Hurlemann Rene Hurlemann Rene Hurlemann Mohamed E. G. Elsayed Mohamed E. G. Elsayed Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis Frontiers in Psychiatry schizophrenia systematic review meta-analysis GLP-1 receptor agonists treatment |
| title | Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis |
| title_full | Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis |
| title_fullStr | Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis |
| title_full_unstemmed | Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis |
| title_short | Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis |
| title_sort | glucagon like peptide 1 receptor agonists treatment for cardio metabolic parameters in schizophrenia patients a systematic review and meta analysis |
| topic | schizophrenia systematic review meta-analysis GLP-1 receptor agonists treatment |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1153648/full |
| work_keys_str_mv | AT abdulrhmankhaity glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis AT nadamostafaaldardery glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis AT khaledalbakri glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis AT omaraabdelwahab glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis AT mahmoudtarekhefnawy glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis AT yamanasyousef glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis AT ruaaetaha glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis AT saryaswed glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis AT waelhafez glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis AT waelhafez glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis AT renehurlemann glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis AT renehurlemann glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis AT renehurlemann glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis AT mohamedegelsayed glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis AT mohamedegelsayed glucagonlikepeptide1receptoragoniststreatmentforcardiometabolicparametersinschizophreniapatientsasystematicreviewandmetaanalysis |